Molecular Oncology, EarlyView.This study identifies nuclear YB‐1 S102 phosphorylation as a marker associated with KRAS and FBXW7 mutations in colorectal cancer. Mutated KRAS correlates specifically with nuclear, not cytoplasmic, S102 YB‐1. These findings provide the first ex vivo evidence of this link in CRC and suggest future studies should assess the prognostic and therapeutic ...
Konstanze Lettau +9 more
wiley +1 more source
Th1-mediated intestinal inflammation in Crohn's disease may be induced by activation of lamina propria lymphocytes through synergistic stimulation of interleukin-12 and interleukin-18 without T cell receptor engagement [PDF]
, 2002 Akira Okazawa
openalex +3 more sources
Clinical Remission Criteria and Serum Levels of Type 2 Inflammation Mediators during 24 Weeks of Treatment with the Anti-IL-5 Drug Mepolizumab in Patients with T2-High Severe Asthma. [PDF]
Diagnostics (Basel)Palacionyte J +5 more
europepmc +1 more source
Inhibition of immune‐complex mediated dermal inflammation in rats following either oral or topical administration of a small molecule C5a receptor antagonist [PDF]
, 2001 Anna J. Strachan +4 more
openalex +1 more source
A nucleotide‐independent, pan‐RAS‐targeted DARPin elicits anti‐tumor activity in a multimodal manner
Molecular Oncology, EarlyView.We report a Designed Ankyrin Repeat Protein that binds and inhibits RAS proteins, which serve as central cell signaling hubs and are essential for the progression of many cancers. Its unique feature is that it does not discriminate between different RAS isoforms or mutations and is capable of binding to RAS in both its active (GTP‐bound) and inactive ...
Jonas N. Kapp +13 more
wiley +1 more source
Osteopontin: a key cytokine in cell‐mediated and granulomatous inflammation
, 2000 Anthony O’Regan, Jeffrey S. Berman
openalex +2 more sources
Molecular and cellular mediators of Alzheimer's disease inflammation [PDF]
, 2001 Ron Strohmeyer, Joseph Rogers
openalex +1 more source
Proresolving lipid mediators and mechanisms in the resolution of acute inflammation.
Immunity, 2014 C. Buckley, D. Gilroy, C. Serhan
semanticscholar +1 more source
Molecular Oncology, EarlyView.C–C chemokine receptor type 9 (CCR9) is an immune checkpoint in pancreatic ductal adenocarcinoma (PDAC). Novel anti‐CCR9 antibody SRB2 was evaluated in combination with cytotoxic chemotherapy in PDAC cells, patient‐derived organoids, patient‐derived xenografts, and humanized mouse models.
Hannah G. McDonald +18 more
wiley +1 more source